News Agency
Men's Weekly

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease

  • Written by PR Newswire

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. SKY-0515's Phase 1 study will include healthy volunteers before targeting Huntington's patients. Huntington's disease is a fatal neurological disease with no curative therapies.

WALTHAM, Mass., Oct. 23, 2023 /PRNewswire/ --...

Read more: Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting...

Improving Internal Feedback Loops Through CMS-Based Commenting and Versioning

Collaboration is essential for successful digital content creation. Unfortunately, in many companies, the feedback mechanism between marketing, design, product and development functions is less than cohesive. For example, feedback is left in email chains, instant chat messages, or within locked... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion